LOW MOLECULAR WEIGHT HEPARIN CALIUM COMBINED WITH SHENYANKANGFU TABLET FOR THE TREATMENT OF PRIMARY NEPHROTIC SYNDROME

QIU DONGHAO¹, ZHAO NING²

¹Han nationality, Jiashan, Zhejiang - ²Han nationality, Shaoxing, Zhejiang

Objective: To study the clinical effects of Shenyankangfu tablet combined with low molecular weight heparin calium for pri- mary nephrotic syndrome (PNS).

Methods: 90 PNS patients treated from May 2013 to May 2014 in our hospital were selected and randomly divided into experi- mental group and control group, 45 cases each group. The experimental group patients were treated with Shenyankangfu tablet com- bined with low molecular weight heparin calium while the control group patients were just treated with low molecular weight hepa- rin calium, two groups patients were treated for 2 months. The clinical effects and clinical index like triglyceride, total cholesterol, serum creatinine, serum albumin, urine protein quantification in the two groups were compared before and after surgery, as well as the coagulation indicators of two groups were observed.

Result: The effective rate of experimental group (88.9%) was significantly higher than that of control group (66.7%) (P< 0.05); the index like triglyceride, total cholesterol, serum creatinine, serum albumin, urine protein quantification of experimental group was significantly better than that of control group (P<0.05); the coagulation indicators like D- dimer (D-D), fibrinogen (Fib), prothrombin time (PT), activated partial thromboplastin time (APTT) of experimental group was significantly better than that of control group (P<0.05).

Conclusion: For PNS patients, Shenyankangfu tablet combined with low molecular weight heparin calium has an obvious clinical effect and can significantly improve the hypercoagulable state and renal functions. It is worthy of clinical promotion.